Mercer Global Advisors
MITO

Mercer Global Advisors’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Mercer Global Advisors’s Portfolio MITO Stock Details MITO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$75K – 1694
2020
Q4 		$75K Buy
+50,000
New +$70.2K ﹤0.01% 1307

Other funds holding MITO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mercer Global Advisors's MITO Position: Q1 2021 in Review

Mercer Global Advisors sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q1 2021, closing a stake of 50,000 shares — an estimated $75K sold.

Mercer Global Advisors first reported a position in MITO in Q4 2020 and held it in 1 quarter. The position peaked at $75K in Q4 2020. 13 funds tracked by Wall St. Rank hold MITO as of Q1 2021.

  • Mercer Global Advisors reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q1 2021 after selling out during the quarter.
  • Mercer Global Advisors sold 50,000 Stealth BioTherapeutics Corp. ADS shares in Q1 2021, an estimated $75K.
  • Mercer Global Advisors first reported a position in Stealth BioTherapeutics Corp. ADS in Q4 2020 and held it in 1 quarter.
  • Mercer Global Advisors's Stealth BioTherapeutics Corp. ADS position peaked at $75K in Q4 2020.
  • 13 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q1 2021.

Based on Mercer Global Advisors's 13F filing for Q1 2021, filed 11 May 2021.